Contineum Therapeutics, Inc. Class A Common Stock
Stock Forecast, Prediction & Price Target
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) stock Price Target by analysts
$32
Potential upside: 244.08%
Contineum Therapeutics, Inc. Class A Common Stock price prediction
What is Contineum Therapeutics, Inc. Class A Common Stock stock analysts` prediction?
Contineum Therapeutics, Inc. Class A Common Stock stock forecast: Based on 1 Wall Street analysts` predicted price targets for Contineum Therapeutics, Inc. Class A Common Stock in the last 3 months, the avarage price target is $32, with a high forecast of $NaN. The average price target represents a 244.08% change from the last price of $9.3.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Contineum Therapeutics, Inc. Class A Common Stock stock Price Target by analysts
Full breakdown of analysts given Contineum Therapeutics, Inc. Class A Common Stock price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Joel Beatty Robert W. Baird | 0% 0/1 | 11 months ago | $32 244.08% upside | $16.07 | StreetInsider | Previous targets (0) |
Brian Abrahams RBC Capital | 0% 0/1 | over 1 year ago | $30 222.58% upside | $16 | TheFly | Previous targets (0) |
Paul Matteis Stifel Nicolaus | 0% 0/1 | over 1 year ago | $29 211.82% upside | $16 | StreetInsider | Previous targets (0) |
FAQ
What is the best performing analyst?
In the last twelve months 1 analysts have been covering Contineum Therapeutics, Inc. Class A Common Stock stock. The most successful analyst is Joel Beatty.